Binding of mepartricin to sex hormones, a key factor of its activity on benign prostatic hyperplasia

Arzneimittel-Forschung/Drug Research

Volumn 51, Issue 12, 2001, Pages 984-990

  Barone, D ^a   Peroglio, F ^a   Toso, E ^a   Bruzzese, T ^a  

^a Società Prodotti Antibiotici   (Italy)

Author keywords

Androgens; Benign prostatic hyperplasia; CAS 11121 32 7; Estrogens; Ipertrofan ; Mepartricin, complex with sex hormones

Indexed keywords

ANDROSTANOLONE; EPERTROFAN; ESTRADIOL; MEPARTRICIN; SEX HORMONE; TESTOSTERONE;

ARTICLE; BILE; CATTLE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BINDING; DRUG BLOOD LEVEL; HORMONE BINDING; HUMAN; IN VITRO STUDY; INTESTINE; NONHUMAN; PROSTATE HYPERTROPHY; RADIOACTIVITY; SERUM; TEMPERATURE DEPENDENCE;

EID: 0035667463     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300149     Document Type: Article

References (32)

1. The development of human benign prostatic hyperplasia with age
2. Benign prostatic hyperplasia: Antecedents and natural history
3. Testosterone action in the rat ventral prostate
4. The pathogenesis of benign prostatic hyperplasia
5. The effect of finasteride in men with benign prostatic hyperplasia
6. Binding and functional properties of doxazosin in the human prostate adenoma and canine brain
7. Phytotherapy in treatment of benign prostatic hyperplasia: A critical review
8. Age variation of the 24-hour mean plasma concentrations of androgens, estrogens and gonadotropins in normal adult men
9. Steroid hormones and the pathogenesis of benign prostatic hyperplasia
10. Age related changes in free plasma testosterone, dihydrotestosterone and estradiol
11. Urinary hormone excretion in benign prostatic hyperplasia
12. Nuclei of stroma: Site of highest estrogen concentration in human benign prostatic hyperplasia
13. Steroid hormone receptors in the prostate
14. Histologic localization of estrogen receptors in normal and diseased human prostates by immunocytochemistry
15. Androgens and estrogens: Their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate
16. Androgen- and estrogen-receptor content in spontaneous and experimentally induced canine prostatic hyperplasia
17. The role of estrogen/androgen synergism in the pathogenesis of benign prostatic hyperplasia
18. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia
19. Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation
20. Partricin methyl ester, a semisynthetic polyene antibiotic
21. A double-blind study of the effects of mepartricin in the treatment of obstruction due to benign prostatic hyperplasia
22. Double-blind, placebo-controlled trial to assess the efficacy and tolerability of mepartricin in the treatment of BPH
23. Estrogen suppression as a pharmacotherapeutic strategy in the medical treatment of benign prostatic hyperplasia: Evidence for its efficacy from studies with mepartricin
24. Pharmacokinetics of mepartricin. Note 1: Absorption and excretion of its insoluble form
25. Observations on some hormone fractions in patients with benign prostatic hyperplasia treated with mepartricin
26. Faecal elimination of steroids in rats after oral administration of mepartricin
27. Effects of mepartricin, a polyene macrolide agent, on fecal excretion and serum concentration of estrogen and number of prostatic estrogen receptors in immature rats
28. Effects of mepartricin (S-160) on spontaneous canine benign prostatic hyperplasia
29. Metabolism of estrogens - Natural and synthetic
30. Biliary excretion and intestinal metabolism of progesterone and estrogens in man